🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

Recruitingn/aAges 18 Years - 80 YearsAllUniversity Hospital Heidelberg
NCT04265040 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity. This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. "Clinical phenotyping, follow-up \& biosampling" 2. "Genomics", 3. "Inflammation" and 4. "Biomarker". The central aims ar

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Non-ischemic structural cardiomyopathies * Age ≥ 18 or ≤ 80 years * The patient is able to understand the declaration of consent and to sign it dated * At least one of the following diagnoses depending on the specific TORCH- Plus inclusion / exclusion - SOP: Dilated Cardiomyopathy (DCM) * family / genetic * inflammatory / persistent myocarditis * idiopathic (after exclusion secondary cause) * left sided systolic dysfunction (EF ≤ 45%) Left ventricular hypertrophy * sarcomere hypertrophic cardiomoypathia (HCM, HOCM) * amyloid (AL: light chains, TTR: transthyretin, wild type) Left ventricular non-compaction cardiomyopathy (LVNC) Arrhythmogenic right ventricular cardiomyopathy (ARVC / D) Exclusion Criteria: The following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion / exclusion - SOP in detail: * Age: \<18 years or\> 80 years * Patient has other (cardiac) previous illnesses: * uncontrollable arterial hypertension * primary pulmonary arterial hypertension * radiation therapy in the chest area * addiction (drug or alcohol abuse) * life expectancy \<1 year due to non-cardiological pre-existing conditions * significant heart valve disease * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly) * chemotoxic cardiomyopathy * condition after myocarditis * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus) * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV) * Tachymyopathy
💊

What it tests

  • Not listed
📍

Where

1 site
University Hospital Heidelberg - Clinic of Cardiology, Angiology and Pneumology
Heidelberg, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy